Cortes J, Quintás-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011. https://doi.org/10.1002/cncr.25527.

Article  PubMed  Google Scholar 

O’Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003. https://doi.org/10.1056/nejmoa022457.

Article  PubMed  Google Scholar 

Deininger M, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009. https://doi.org/10.1182/blood.v114.22.1126.1126.

Article  PubMed  PubMed Central  Google Scholar 

Jabbour E, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009. https://doi.org/10.1182/blood-2008-04-154344.

Article  PubMed  PubMed Central  Google Scholar 

Hochhaus A, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008. https://doi.org/10.1038/leu.2008.84.

Article  PubMed  Google Scholar 

Kantarjian HM, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011. https://doi.org/10.1182/blood-2010-03-277152.

Article  PubMed  PubMed Central  Google Scholar 

Cortes JE, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011. https://doi.org/10.1182/blood-2011-05-355594.

Article  PubMed  PubMed Central  Google Scholar 

Kantarjian HM, et al. Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood. 2007. https://doi.org/10.1182/blood.v110.11.1047.1047.

Article  PubMed  PubMed Central  Google Scholar 

Marin D, et al. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses [7] (multiple letters). Blood. 2003. https://doi.org/10.1182/blood-2003-06-2042.

Article  PubMed  Google Scholar 

Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res. 2003;9(6):2092–7.

CAS  PubMed  Google Scholar 

Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005. https://doi.org/10.1182/asheducation-2005.1.183.

Article  PubMed  Google Scholar 

Garcia-Gutierrez JV, et al. Impact of second-generation tyrosine kinase inhibitors as second line treatment for patients with chronic myeloid leukemia. Blood. 2011. https://doi.org/10.1182/blood.v118.21.3780.3780.

Article  Google Scholar 

O’Hare T, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005. https://doi.org/10.1158/0008-5472.CAN-05-0259.

Article  PubMed  Google Scholar 

Shah NP et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (80-. ). 2004. https://doi.org/10.1126/science.1099480.

Hochhaus A, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007. https://doi.org/10.1182/blood-2006-09-047266.

Article  PubMed  Google Scholar 

Kantarjian H, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007. https://doi.org/10.1182/blood-2006-11-056028.

Article  PubMed  PubMed Central  Google Scholar 

O’Brien SG, et al. Spirit 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML. Blood. 2014. https://doi.org/10.1182/blood.v124.21.517.517.

Article  PubMed  PubMed Central  Google Scholar 

Weisberg E, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005. https://doi.org/10.1016/j.ccr.2005.01.007.

Article  PubMed  Google Scholar 

Hazarika M, et al. Tasigna for chronic and accelerated phase philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res. 2008. https://doi.org/10.1158/1078-0432.CCR-08-0308.

Article  PubMed  Google Scholar 

H-G, G et al. Efficacy of nilotinib versus high-dose imatinib in early chronic phase CML patients who have suboptimal molecular responses to standard-dose imatinib (RE-NICE multicenter study). Blood. 2011;118(21):2765. https://doi.org/10.1182/blood.V118.21.2765.2765.

Nicolini FE, et al. Expanding nilotinib access in clinical trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer. 2012. https://doi.org/10.1002/cncr.26249.

Article  PubMed  Google Scholar 

Hughes TP, et al. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 2017;31:2529.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yeung DT, et al. TIDEL-Ii: First-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015. https://doi.org/10.1182/blood-2014-07-590315.

Article  PubMed  PubMed Central  Google Scholar 

Hochhaus A, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016. https://doi.org/10.1038/leu.2016.5.

Article  PubMed  PubMed Central  Google Scholar 

Steinbach A, Clark SM, Clemmons AB. Bosutinib: a novel Src/Abl kinase inhibitor for chronic myelogenous leukemia. J Adv Pract Oncol. 2013. https://doi.org/10.6004/jadpro.2013.4.6.8.

Cortes JE, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2017.74.7162.

Article  PubMed  PubMed Central  Google Scholar 

Soverini S, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014. https://doi.org/10.1016/j.leukres.2013.09.011.

Article  PubMed  Google Scholar 

Kaehler M, Cascorbi I. Pharmacogenomics of impaired tyrosine kinase inhibitor response: lessons learned from chronic myelogenous leukemia. Front Pharmacol. 2021. https://doi.org/10.3389/fphar.2021.696960.

Article  PubMed  PubMed Central  Google Scholar 

Morozova EV, Vlasova YY, Pryanishnikova MV, Lepik KV, Afanasyev BV. Efficacy of dasatinib in a CML patient in blast crisis with F317L mutation: a case report and literature review. Biomark Insights. 2015. https://doi.org/10.4137/BMI.S22438.

Article  PubMed  PubMed Central  Google Scholar 

Balabanov S, Braig M, Brümmendorf TH. Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discov Today Technol. 2014. https://doi.org/10.1016/j.ddtec.2014.03.003.

Article  PubMed  Google Scholar 

MeenakshiSundaram DN, et al. Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. Drug Discovery Today. 2019. https://doi.org/10.1016/j.drudis.2019.05.007.

Article  Google Scholar 

Jabbour E, et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. 2011. https://doi.org/10.1002/cncr.25717.

Article  PubMed  Google Scholar 

Müller MC, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009. https://doi.org/10.1182/blood-2009-04-214221.

Article  PubMed  PubMed Central  Google Scholar 

Hughes T, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009. https://doi.org/10.1200/JCO.2009.21.8230.

Article  PubMed  PubMed Central  Google Scholar 

Kantarjian HM, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014. https://doi.org/10.1182/blood-2013-07-513937.

Article  PubMed  PubMed Central  Google Scholar 

Hochhaus A, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020. https://doi.org/10.1038/s41375-020-0776-2. This paper is of importance as it serves as the official guidelines and recommendations by the European LeukemiaNet panel for the monitoring and reatment of CML in the first line and second line, along with side effects that must be considered with each TKI.

Article  PubMed  PubMed Central  Google Scholar 

Soverini S, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011. https://doi.org/10.1182/blood-2010-12-326405.

Article  PubMed  PubMed Central  Google Scholar 

Castagnetti F, et al. Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors. Blood. 2019. https://doi.org/10.1182/blood-2019-127514. This abstract was of particular importance as it was phase 2 single arm study showing the tolerability of bosutinib in elderly patients who have previously failed first line TKIs.

Article  Google Scholar 

Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020. https://doi.org/10.1016/j.ccell.2020.03.006. This paper is of importance as it is an in-depth review of mechanism that leads to TKI resistance and strategies to overcome resistance.

Article  PubMed  PubMed Central  Google Scholar 

O’Hare T, et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009. https://doi.org/10.1016/j.ccr.2009.09.028.

Article  PubMed